APAC Life Sciences Valuation Trends: Chinese Firms Eclipse Japan, India Peers

The top listed Chinese healthcare and life sciences companies have had a strong run on the stock market over the recent past, including during the COVID-19 outbreak, with price-to-earnings (PE) multiples dwarfing peers in markets like India and Japan and even ahead of US big pharma in some instances.

Addressing a recent webinar, Varun Gupta, managing director and Asia Pacific leader, valuation advisory at Duff & Phelps (part of Kroll), noted that the sector in China had performed “fantastically well”, even though the rest of the Chinese market has not had as much of a bull run as Indian bourses have witnessed